Stockscreener 앱 받기
6.94
4.52%
0.30
시장 영업 전:
6.41
-0.53
-7.64%
전일 마감가:
$6.64
열려 있는:
$6.72
하루 거래량:
2.24M
Relative Volume:
0.83
시가총액:
$1.99B
수익:
$9.77M
순이익/손실:
$-109.00M
주가수익비율:
-19.26
EPS:
-0.3604
순현금흐름:
$-93.83M
1주 성능:
+10.16%
1개월 성능:
+58.81%
6개월 성능:
+72.21%
1년 성능:
+182.11%
1일 변동 폭
$6.565
$6.95
1주일 범위
$6.11
$6.95
52주 변동 폭
$1.845
$6.95
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
6.94 | 1.99B | 9.77M | -109.00M | -93.83M | -0.3604 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Raymond James | Strong Buy |
| 2025-07-11 | 개시 | BofA Securities | Buy |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-04-09 | 개시 | Piper Sandler | Overweight |
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
Taysha Gene earnings loom with pivotal trial data on horizon By Investing.com - Investing.com South Africa
Taysha Gene Therapies stock hits 52-week high at 6.77 USD - Investing.com
Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday - MarketBeat
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Five new Taysha hires get 188,000 stock units under Nasdaq rule - Stock Titan
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - Investing News Network
Biotech Taysha pairs its Q1 results with a corporate update on May 6 - Stock Titan
Earnings update from Taysha Gene Therapies expected next week - Traders Union
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call ... - Caledonian Record
Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge? - Yahoo Finance
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting - Investing News Network
Taysha to present preclinical data on Rett syndrome gene therapy By Investing.com - Investing.com Canada
Taysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual Meeting - Quiver Quantitative
Taysha Gene Therapies to Present New Preclinical Data - GlobeNewswire
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Taysha Gene Therapies Shares Surge After FDA Grants Breakthrough Therapy Status - MSN
Taysha Gene Therapies stock hits 52-week high at 6.7 USD - Investing.com India
Taysha Gene Therapies, Inc. ($TSHA) CEO and Director 2025 Pay Revealed - Quiver Quantitative
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month HighShould You Buy? - MarketBeat
Taysha Gene Therapies stock hits 52-week high at 6.7 USD By Investing.com - Investing.com South Africa
Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels - Insider Monkey
Executive pay, board seats and auditor up for TSHA (NASDAQ: TSHA) vote - Stock Titan
This is why Taysha Gene Therapies, Inc. (TSHA) is one of the best healthcare penny stocks to buy - MSN
Taysha Gene Therapies (TSHA) making progress on crucial Rett syndrome treatment - MSN
TSHA Stock Jumps As Canaccord Hikes Price Target - StocksToTrade
TSHA Jumps As Canaccord Hikes Price Target On Trial Progress - timothysykes.com
Taysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial Data - MSN
TSHA Jumps As Taysha Gene Therapies Wins Target Hike - StocksToTrade
TSHA Jumps As Taysha Wins Target Hike On Trial Progress - timothysykes.com
Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Exploring a Potential 94% Upside in the Biotech Arena - DirectorsTalk Interviews
Taysha (TSHA) Stock Treasury Trade (Near Lows) 2026-04-16Breakout Signals - Cổng thông tin điện tử Tỉnh Sơn La
Taysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies stock hits 52-week high at 6.02 USD - Investing.com Australia
Unusually active option classes on open April 16th - TipRanks
Taysha Gene Therapies (NASDAQ:TSHA) Sets New 12-Month HighStill a Buy? - MarketBeat
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 9%Should You Buy? - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Taysha Gene Therapies Inc 주식 (TSHA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Apr 10 '26 |
Sale |
4.46 |
200,000 |
892,000 |
1,136,410 |
0.14%
0.48%
자본화:
|
볼륨(24시간):